With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that stocks with competitive advantages, such as best-in-class or first-in-class candidates, have underpinned its thesis.

Out of 10 buy-rated stocks, analyst

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.